Auckland-based AFT Pharmaceuticals (ASX:AFP) recorded sustained double-digit sales growth across its entire global portfolio for the March quarter of 2026.
The momentum has propelled the company towards record-breaking annual sales, with official FY26 financial results scheduled for release on May 21.
Leadership has firmed up operating earnings guidance, projecting a range between NZ$20 million and NZ$24 million, while reiterating a confident trajectory towards a NZ$300 million revenue target for the 2027 financial year.
A driver of the optimism is the company's strategic penetration into the United States market.
AFT has secured a high-profile partnership with Cost Plus, the public benefit pharmacy chain backed by billionaire Mark Cuban.
The deal focuses on the distribution of Maxigesic Rapid tablets (marketed as Combogesic Rapid in the US), providing a substantial platform for the analgesic in a competitive landscape.
Beyond North America, the company is seeing the fruits of its international integration efforts.
In South Africa, AFT has incorporated newly acquired hospital drugs into its local operations, with these assets expected to contribute meaningfully to both revenue and earnings by FY27.
On the clinical front, the company continues to advance its Novel Iron Injection Project, following constructive regulatory meetings with the US FDA.
Managing Director Dr Hartley Atkinson noted that the company’s success in new business hubs is mirroring the dynamics of its established Australasian operations.